PMS2 and neoplasm: When MSI-H and lack of expression of both MLH1 and PMS2 are observed, tumor BRAF V600E mutation and/or MLH1 promoter hypermethylation testing is recommended to distinguish sporadic colorectal cancer from CRC caused by an MMR defective system [13,52,62,66].